Fibrates — including fenofibrate, gemfibrozil, and bezafibrate — exert their primary effects through activation of peroxisome proliferator-activated receptor alpha (PPAR-α), a nuclear receptor expressed predominantly in the liver, skeletal muscle, heart, and kidney.¹ PPAR-α activation produces a coordinated transcriptional program that reduces triglyceride synthesis and increases triglyceride catabolism: it upregulates lipoprotein lipase (LPL) expression, increasing hydrolysis of very low-density lipoprotein (VLDL) and chylomicron triglycerides; downregulates apolipoprotein C-III (apoC-III), a natural inhibitor of LPL, thereby further enhancing TG clearance; upregulates apolipoprotein A-I and A-II expression, increasing high-density lipoprotein cholesterol (HDL-C); and reduces hepatic VLDL synthesis by inhibiting free fatty acid flux to the liver.¹ The net lipid effects are: triglyceride reduction of 20–50%, HDL-C increase of 10–20%, and variable low-density lipoprotein cholesterol (LDL-C) effects (modest reduction in most patients; paradoxical LDL-C increase in patients with severe hypertriglyceridemia as VLDL is converted to LDL after triglyceride (TG) hydrolysis). PPAR-α activation also has anti-inflammatory effects — reducing fibrinogen, CRP, and interleukin-6 — and reduces uric acid by increasing renal uric acid excretion, a clinically relevant secondary benefit in patients with gout or hyperuricemia.¹

Fenofibrate is the most widely used fibrate in contemporary practice. Available in multiple formulations (micronized capsules, tablets, nanocrystal) with doses typically 48–145 mg or 54–160 mg depending on formulation. It is a prodrug converted by esterases to fenofibric acid, which is the active moiety. Fenofibrate does not significantly inhibit CYP2C9 (cytochrome P450 2C9) or glucuronidation of statins and therefore carries substantially lower pharmacokinetic interaction risk with statins than gemfibrozil.¹ Renal excretion is predominant; dose reduction or avoidance is required in CKD (estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m²). Fenofibrate modestly increases serum creatinine via a reversible reduction in creatinine tubular secretion — not a marker of nephrotoxicity but a clinically important consideration in CKD monitoring.

Gemfibrozil is the fibrate most strongly associated with statin drug interaction risk. Gemfibrozil inhibits OATP1B1 (the hepatic uptake transporter for statins) and inhibits glucuronidation of statin lactone metabolites, markedly increasing plasma concentrations of simvastatin, cerivastatin, and rosuvastatin.¹ The gemfibrozil-cerivastatin combination was responsible for the fatal rhabdomyolysis cases that led to cerivastatin's 2001 market withdrawal. Co-administration of gemfibrozil with any statin significantly increases myopathy risk — the combination is generally avoided in clinical practice when fenofibrate is an available and equally effective alternative. Gemfibrozil's 600 mg twice-daily dosing (with meals) also offers no adherence advantage over once-daily fenofibrate. Bezafibrate (not available in the US; available in Europe, Canada, and other markets) has a more balanced PPAR-α/PPAR-γ/PPAR-δ activation profile (pan-PPAR activity) and has demonstrated some evidence of atherosclerotic cardiovascular disease (ASCVD) event reduction in trials (Bezafibrate Infarction Prevention study (BIP) — Bezafibrate Infarction Prevention study), though the results were not statistically significant in the overall trial.

The hypothesis that raising HDL-C and lowering TG with fibrates reduces cardiovascular events beyond statin therapy has been tested in several large trials, with consistently disappointing results in patients already on background statin: ACCORD-Lipid (2010) enrolled 5,518 patients with type 2 diabetes on simvastatin and randomized them to fenofibrate or placebo.² The primary endpoint (major cardiovascular events) was not significantly reduced by fenofibrate addition (HR 0.92; p=0.32). A pre-specified subgroup of patients with TG ≥204 mg/dL and HDL-C ≤34 mg/dL showed a nominally favorable trend (HR 0.69) but was not statistically powered to confirm benefit.² This subgroup finding has generated ongoing interest in fibrate use in patients with the "combined dyslipidemia" phenotype (high TG + low HDL-C on statin), but the interaction p-value of 0.057 fell just short of significance and the finding has not been replicated in a dedicated trial.

FIELD (Fenofibrate Intervention and Event Lowering in Diabetes, 2005) enrolled 9,795 patients with type 2 diabetes, predominantly not on statin, and showed a non-significant 11% reduction in the primary endpoint of coronary heart disease events with fenofibrate 200 mg vs. placebo.² The interpretation was complicated by differential statin initiation during the trial (more patients in the placebo arm started statins during the trial, potentially attenuating the fenofibrate effect). PROMINENT (2022) — the Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENTs with Diabetes trial — enrolled 10,497 patients with diabetes, mild-to-moderate hypertriglyceridemia, and low HDL-C on background statin and randomized them to pemafibrate (a selective PPAR-α modulator with greater PPAR-α specificity than traditional fibrates) or placebo.³ Despite robust TG reduction (26%), the trial found no reduction in major adverse cardiovascular events (HR 1.03; p=0.67). PROMINENT was a decisive negative trial for the TG-lowering and HDL-C-raising hypothesis in this population and effectively closed the case against fibrates as add-on cardiovascular therapy in patients with moderately elevated TG on background statin.³

The contemporary role of fibrates in cardiovascular practice is primarily confined to: (1) severe hypertriglyceridemia (TG ≥500–1000 mg/dL) for pancreatitis prevention — fibrates are first-line therapy in this indication, with fenofibrate preferred over gemfibrozil due to the statin interaction risk; (2) consideration in patients with combined dyslipidemia (TG ≥204 mg/dL + HDL-C ≤34 mg/dL on statin) where the residual ASCVD risk from the TG/HDL phenotype is deemed high enough to justify empiric therapy despite the absence of definitive outcomes evidence; and (3) patients intolerant of omega-3 fatty acids where TG lowering is clinically indicated.¹ Fibrates are not recommended as first-line or routine add-on therapy for ASCVD risk reduction in patients on statin therapy with moderately elevated TG alone.

Bile acid sequestrants (BAS) — cholestyramine, colestipol, and colesevelam — are large, positively charged polymeric resins that are not absorbed from the gastrointestinal tract.⁵ They bind bile acids in the intestinal lumen through ionic interactions, interrupting enterohepatic bile acid recirculation. Bile acids are derived from hepatic cholesterol oxidation; their intestinal sequestration depletes the hepatic bile acid pool, stimulating increased hepatic conversion of cholesterol to bile acids to replenish the pool. The resulting decrease in hepatocyte cholesterol content triggers sterol regulatory element-binding protein (SREBP)-2-mediated LDL receptor (LDLR) upregulation — the same compensatory mechanism as statins and ezetimibe — increasing low-density lipoprotein cholesterol (LDL-C) clearance from plasma.⁵ BAS reduce LDL-C by 15–30% depending on dose and formulation. They modestly increase triglyceride (TG) levels (typically 5–10%) due to compensatory upregulation of hepatic very low-density lipoprotein (VLDL) synthesis in response to reduced hepatic cholesterol content — a consideration that limits their use in patients with pre-existing hypertriglyceridemia. High-density lipoprotein cholesterol (HDL-C) is modestly increased (3–5%).

Cholestyramine and colestipol are older, granular powder formulations requiring reconstitution in liquid and taken 1–2 times daily, typically 4–24 g/day. Palatability is a significant tolerability issue — the gritty texture and gastrointestinal adverse effects (constipation, bloating, flatulence, nausea) contribute to high discontinuation rates. They were among the first agents shown to reduce cardiovascular events in the pre-statin era: the Lipid Research Clinics Coronary Primary Prevention Trial (Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), 1984) demonstrated that cholestyramine reduced coronary events in hypercholesterolemic men.⁵ Colesevelam (Welchol) is a newer, more selective bile acid-binding agent available as tablets (3.75 g/day in divided doses or as a single daily dose of 6 tablets) or oral suspension. It is better tolerated than cholestyramine/colestipol due to improved palatability and lower gastrointestinal (GI) adverse effect rate, though constipation remains common.⁵ Colesevelam has a unique additional indication: it modestly reduces HbA1c (approximately 0.5%) in patients with type 2 diabetes through incompletely understood mechanisms involving altered bile acid signaling on glucagon-like peptide-1 (GLP-1) secretion and hepatic glucose metabolism, making it potentially useful in the small subset of patients with combined hypercholesterolemia and diabetes requiring LDL-C lowering without systemic drug exposure.

The most clinically important adverse property of BAS is their non-specific binding of co-ingested medications, which can significantly reduce the absorption of: fat-soluble vitamins (A, D, E, K); warfarin; thyroid hormone (levothyroxine); digoxin; statins; fibrates; thiazide diuretics; beta-blockers; and a range of other drugs.⁵ All other oral medications should be taken at least 1 hour before or 4–6 hours after the BAS dose to avoid absorption interference. This interaction requirement substantially complicates prescribing in polypharmacy patients and is a practical limitation on BAS use in the typical cardiovascular patient. Patients on anticoagulation (warfarin), thyroid replacement, and cardiac glycosides require particular vigilance.

BAS occupy a narrow but defined clinical niche: (1) adjunctive LDL-C lowering in statin-intolerant patients who cannot tolerate systemic LDL-C-lowering agents and in whom ezetimibe alone is insufficient; (2) LDL-C lowering in pregnancy (cholestyramine, colestipol, and colesevelam are not systemically absorbed and carry no fetal risk — the only pregnancy-compatible LDL-C-lowering options); (3) pediatric hypercholesterolemia (FH children), where systemic drug exposure is a concern; and (4) as combination therapy with statins and/or ezetimibe in patients with FH or very high LDL-C not at target on statin plus ezetimibe, particularly when PCSK9 inhibitor access is limited.⁵ BAS are not appropriate as primary therapy in patients with TG >300 mg/dL given the risk of worsening hypertriglyceridemia.

Icosapentaenoic acid 4 g/day: Indicated (ACC/AHA Class IIa) for adults with established atherosclerotic cardiovascular disease (ASCVD) or diabetes with at least one additional risk factor, on maximally tolerated statin therapy, with triglycerides (TG) 135–499 mg/dL. This is the only agent in this module with an evidence-based recommendation for ASCVD event reduction.⁷ Fibrates (fenofibrate preferred): Indicated for severe hypertriglyceridemia (TG ≥500 mg/dL) to prevent acute pancreatitis. Reasonable consideration (Class IIb, ACC/AHA) for patients with TG ≥500 mg/dL unresponsive to diet, lifestyle, and glucose optimization alone. Not recommended as add-on ASCVD therapy in patients on statin with moderate hypertriglyceridemia after the Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN dIabeTic patiENts (PROMINENT) trial. Colesevelam: Useful adjunctive low-density lipoprotein cholesterol (LDL-C) lowering in statin-intolerant patients, in patients unable to use PCSK9 inhibitors, in pregnancy (FH), and in combined hypercholesterolemia plus type 2 diabetes where a single agent can address both.⁵

Niacin: Not recommended for ASCVD risk reduction in patients on statin therapy. The combination of absent benefit and substantial adverse effects — including excess diabetes, serious gastrointestinal (GI) events, and potentially increased infection risk — makes niacin a therapy that should be discontinued in most patients currently taking it.⁴ Docosahexaenoic acid (DHA)-containing omega-3 preparations: Not recommended for ASCVD event reduction. Over-the-counter fish oil products are not a substitute for prescription IPE and should not be prescribed with the expectation of cardiovascular benefit. Gemfibrozil: Largely supplanted by fenofibrate due to the statin interaction risk; should be avoided in patients on statin therapy.¹

Severe hypertriglyceridemia (TG ≥500–1000 mg/dL), particularly fasting TG ≥1,000 mg/dL, carries acute pancreatitis risk that is independent of its ASCVD implications. The first priority in this setting is TG reduction for pancreatitis prevention, not ASCVD risk reduction. First-line: fenofibrate plus very-low-fat diet (<15% fat calories), alcohol cessation, and glucose optimization. Second-line: high-dose IPE (if TG <500 mg/dL after initial therapy) or novel agents such as volanesorsen (an apoC-III antisense oligonucleotide, approved for familial chylomicronemia syndrome) or olezarsen (an apoC-III siRNA in late-phase trials).⁷ In the acute setting of pancreatitis from severe hypertriglyceridemia, insulin infusion (to activate lipoprotein lipase (LPL)) and plasmapheresis are employed in severe refractory cases.

A systematic side-by-side comparison of the four drug classes in this module is essential for clinical reasoning and discrimination questions. The following framework organizes each class by the five dimensions most relevant to prescribing decisions.

Fibrates — mechanism: peroxisome proliferator-activated receptor alpha activation; primary lipid effect: triglyceride reduction 20 to 50 percent, high-density lipoprotein cholesterol increase 10 to 20 percent, variable low-density lipoprotein cholesterol effect; cardiovascular outcomes evidence: negative in most trials on background statin (ACCORD-Lipid, PROMINENT); current clinical role: severe hypertriglyceridemia above 500 milligrams per deciliter for pancreatitis prevention; preferred agent: fenofibrate (lower statin interaction risk than gemfibrozil); key contraindication: avoid gemfibrozil with statins; avoid all fibrates when triglycerides are in the chylomicronemia range without dietary fat restriction.

Niacin — mechanism: inhibition of hepatic diacylglycerol acyltransferase 2 and reduced hepatocyte free fatty acid delivery, reducing very low-density lipoprotein synthesis; primary lipid effect: triglyceride reduction 20 to 40 percent, high-density lipoprotein cholesterol increase 15 to 35 percent (the largest high-density lipoprotein cholesterol increase of any available drug), low-density lipoprotein cholesterol reduction 15 to 18 percent; cardiovascular outcomes evidence: negative in outcome trials on background statin (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides, Heart Protection Study 2: Treatment of HDL to Reduce the Incidence of Vascular Events); current clinical role: essentially none in contemporary practice — discontinued in most patients currently receiving it; key adverse effects: flushing (prostaglandin-mediated, mitigated by aspirin pretreatment), new-onset diabetes, hepatotoxicity at high doses, hyperuricemia.

Bile acid sequestrants — mechanism: intestinal bile acid binding preventing enterohepatic recirculation, forcing hepatic synthesis of new bile acids from cholesterol, depleting intracellular cholesterol, and upregulating low-density lipoprotein receptor expression; primary lipid effect: low-density lipoprotein cholesterol reduction 15 to 25 percent; no effect on triglycerides (may raise triglycerides in hypertriglyceridemic patients); modest high-density lipoprotein cholesterol increase; cardiovascular outcomes evidence: pre-statin era evidence of event reduction (Lipid Research Clinics Coronary Primary Prevention Trial with cholestyramine); current clinical role: narrow niche in statin-intolerant patients, pregnancy, pediatric familial hypercholesterolemia, and combined hypercholesterolemia plus diabetes (colesevelam); key limitation: drug absorption interactions requiring timing separation from all other medications.

Omega-3 fatty acids — mechanism: icosapentaenoic acid ethyl ester reduces very low-density lipoprotein triglyceride synthesis, reduces platelet aggregability, has anti-inflammatory effects on vascular endothelium, and may reduce atherosclerotic plaque vulnerability through mechanisms beyond triglyceride lowering; primary lipid effect: triglyceride reduction 20 to 30 percent at 4 grams per day; low-density lipoprotein cholesterol effect is neutral to modestly lowering with icosapentaenoic acid ethyl ester (unlike docosahexaenoic acid-containing products, which raise low-density lipoprotein cholesterol); cardiovascular outcomes evidence: positive for icosapentaenoic acid ethyl ester in Reduction of Cardiovascular Events with Icosapentaenoic Acid-Intervention Trial (relative risk reduction 25 percent); negative for docosahexaenoic acid-containing products (Statin Residual Risk Reduction with EpaNova in High Cardiovascular Risk Patients with Hypertriglyceridemia, VITAL); current clinical role: icosapentaenoic acid ethyl ester 4 grams per day as add-on in patients with established atherosclerotic cardiovascular disease or diabetes with additional risk factors, on maximally tolerated statin, with triglycerides 135 to 499 milligrams per deciliter.

Several novel lipid-modifying agents have received regulatory approval or are in late-phase development and are increasingly relevant to clinical practice in patients with complex dyslipidemia, familial hypercholesterolemia, or statin intolerance. Awareness of these agents is important for both clinical practice and for understanding the direction of lipid pharmacology.

Bempedoic acid (Nexletol) is an inhibitor of adenosine triphosphate-citrate lyase, an enzyme upstream of 3-hydroxy-3-methylglutaryl coenzyme A reductase in the cholesterol synthesis pathway. Because adenosine triphosphate-citrate lyase requires activation by a liver-specific enzyme (very long-chain acyl-coenzyme A synthetase 1) that is absent in skeletal muscle, bempedoic acid does not accumulate in muscle tissue and does not cause the myotoxicity associated with statins. This makes it particularly attractive for statin-intolerant patients. As monotherapy, bempedoic acid reduces low-density lipoprotein cholesterol by approximately 18 to 21 percent; in combination with ezetimibe (available as a fixed-dose combination tablet, Nexlizet), low-density lipoprotein cholesterol reduction approaches 38 percent. The Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial (2023) enrolled 13,970 statin-intolerant patients with or at high risk for atherosclerotic cardiovascular disease and demonstrated a 13 percent relative risk reduction in the primary composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization, with an absolute risk reduction of 1.6 percentage points over a median of 40 months — providing definitive cardiovascular outcomes evidence for a non-statin oral low-density lipoprotein cholesterol-lowering agent in statin-intolerant patients.

Adverse effects include gout and hyperuricemia (adenosine triphosphate-citrate lyase inhibition increases plasma uric acid) and a small increase in tendon injury risk.

Volanesorsen (Waylivra) is an antisense oligonucleotide targeting apolipoprotein C-III messenger ribonucleic acid, reducing synthesis of apolipoprotein C-III — an endogenous inhibitor of lipoprotein lipase. Reduced apolipoprotein C-III increases lipoprotein lipase-mediated triglyceride hydrolysis and reduces triglyceride levels by 70 to 80 percent in patients with familial chylomicronemia syndrome (lipoprotein lipase deficiency). It is approved in Europe and Canada for familial chylomicronemia syndrome. A significant limitation is thrombocytopenia, which occurs in a substantial proportion of patients and requires regular platelet monitoring; the Risk Evaluation and Mitigation Strategy program governs its use in approved markets. For patients with familial chylomicronemia syndrome who are unresponsive to dietary fat restriction alone and face recurrent pancreatitis, volanesorsen represents a meaningful therapeutic advance.

Olezarsen is a GalNAc-conjugated antisense oligonucleotide targeting apolipoprotein C-III with hepatocyte-specific delivery, designed to achieve the triglyceride-lowering effects of volanesorsen with reduced systemic exposure and a more favorable thrombocytopenia profile. Phase 3 trial data (BRIDGE-TIMI 73a) showed 60 percent triglyceride reduction without significant thrombocytopenia, and regulatory review is ongoing. If approved, olezarsen would represent a safer alternative to volanesorsen for severe hypertriglyceridemia and familial chylomicronemia syndrome.

Pemafibrate is a selective peroxisome proliferator-activated receptor alpha modulator with greater receptor selectivity than conventional fibrates, designed to reduce triglycerides with fewer off-target effects. Despite this rationale, the PROMINENT trial (2022) in patients with type 2 diabetes and hypertriglyceridemia demonstrated no cardiovascular event reduction despite significant triglyceride lowering, reinforcing the conclusion that triglyceride reduction per se does not translate to reduced atherosclerotic cardiovascular disease events in the modern statin era. Pemafibrate is not approved in the United States; its trial data substantially weakened the case for fibrates in triglyceride-mediated residual risk reduction beyond statin therapy.